Neurocrine Biosciences, Inc.
https://www.neurocrine.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Neurocrine Biosciences, Inc.
Stockwatch: Pandemic Cuts Deep Into Early Commercial Biotech
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
COVID-19 Still Dampens Neurocrine Revenues Despite Industry’s Q3 Uptick
The pandemic has hit psychiatry offices hard, and the company’s management said it anticipates flat sequential revenues in Q4.
Torrent Expects Indian Dapagliflozin Ruling In Q3
With the India business on the road to recovery and the US growth outlook muted, Torrent hopes to keep the boat steady in fiscal 2021. It also expects an order in Q3 in a patent infringement case pertaining to AstraZeneca’s Farxiga, where it and multiple Indian firms are seeking to launch generic versions.
Torrent Expects India Ruling On AZ's Farxiga In Q3
With the India business on the road to recovery and the US growth outlook muted, Torrent hopes to keep the boat steady in fiscal 2021. It also expects an order in Q3 in a patent infringement case pertaining to AstraZeneca’s Farxiga, where it and multiple Indian firms are seeking to launch generic versions.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals